

# **U.S. Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Fine-needle Aspiration, Core, Surgical, Skin Biopsy/Punch Biopsy), By Application, By Site, And Segment Forecasts, 2023 - 2030**

<https://marketpublishers.com/r/UFAB77340994EN.html>

Date: January 2023

Pages: 155

Price: US\$ 5,950.00 (Single User License)

ID: UFAB77340994EN

## **Abstracts**

This report can be delivered to the clients within 2 Business Days

### **U.S. Cancer Biopsy Market Growth & Trends**

The U.S. cancer biopsy market is expected to reach USD 20.18 billion by 2030, registering a CAGR of 11.12% from 2023 to 2030 according to a new report by Grand View Research, Inc. The growth of the U.S. cancer biopsy market is attributed to the rise in the adoption of biopsies based on multi-parametric magnetic resonance imaging and the increasing popularity of image-guided needle biopsies in precision medicine applications.

The liquid biopsy industry is anticipated to expand at an exponential rate in the coming years, wherein increasing investments and strategic initiatives by the companies involved in biopharmaceutical manufacturing & genomic data analysis are anticipated to play a central role. In April 2022, Global Brain invested in Craif, Inc. to develop a novel noninvasive urinary liquid biopsy for the early detection of cancer.

Furthermore, the advent of liquid biopsies, rising clinical implementation of biopsies, and advancements in quality & payment pertaining to genetic cancer diseases are the factors expected to boost the market growth in the coming years. The increasing prevalence of cancer and the growing geriatric population are also likely to fuel market growth.

Moreover, the advent of blood-based multi-cancer early detection (MCED) technologies is going to offer lucrative opportunities during the forecast period. MCED represents a paradigm shift in how cancers will be diagnosed and treated in the future. The great promise of MCED is that it will enable clinicians to convert from screening a few cancers to screening individuals for many cancers.

Companies such as GRAIL, Exact Sciences Corporation are developing MCED tests. In addition, the National Cancer Institute (NCI) is looking at ways to study and evaluate MCED tests. NCI is currently designing clinical trials & other research opportunities for MCED tests, and recently issued a request for information from test developers on their readiness to participate in research initiatives.

Key companies operating in the U.S. cancer biopsy market have adopted several strategic initiatives to reinforce their market presence. Major undertakings by the market participants are mergers & acquisitions, collaborations & partnerships, regional expansions, and new product launches. For instance, in April 2022, Medtronic entered into collaboration with GE Healthcare to address the increasing need for outpatient care. Under this initiative, customers can access financial solutions, extensive product portfolios, and exceptional services.

## U.S. Cancer Biopsy Market Report Highlights

Fine-needle aspiration segment held a dominant share in 2022 owing to the effective and quick test for determining the status of uncertain tissue

Pharma & biopharma discovery & development segment is projected to grow at the fastest rate during the forecast period owing to the increasing demand for developing novel drug candidates

Breast cancer segment is the highest revenue-generating segment in the U.S. cancer biopsy market in 2022 owing to the increasing prevalence of breast cancer

North America dominated the U.S. cancer biopsy market in 2022, which is attributed to preventive measures undertaken by the governments to stop the progression of diseases

## Contents

### CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Research Methodology
- 1.2 Research Assumptions
  - 1.2.1 Estimates And Forecast Timeline
- 1.3 Research Methodology
- 1.4 Information Procurement
  - 1.4.1 Purchased Database
  - 1.4.2 Gvr's Internal Database
  - 1.4.3 Secondary Sources
    - 1.4.3.1 Primary Research
  - 1.4.4 Details Of Primary Research
- 1.5 Information Or Data Analysis
  - 1.5.1 Data Analysis Models
    - 1.5.1.1 End-Use Landscape Assessment
    - 1.5.1.2 Market Origin Assessment
    - 1.5.1.3 Oncology Diagnosis: Market Competition Analysis
- 1.6 Market Formulation And Validation
- 1.7 Model Details
  - 1.7.1 Commodity Flow Analysis
    - 1.7.1.1 Approach 1: Commodity Flow Approach
    - 1.7.1.2 Approach 2: Country-wise market estimation using bottom-up approach
- 1.8 U.S. Market: CAGR Calculation
- 1.9 List of Secondary Sources
- 1.10 List of Primary Sources
- 1.11 Objectives
  - 1.11.1 Objective
  - 1.11.2 Objective
  - 1.11.3 Objective
  - 1.11.4 Objective

### CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Market Outlook

### CHAPTER 3 MARKET VARIABLES, TRENDS, AND SCOPE

- 3.1 Cancer Medical Tourism Within & Outside the U.S.
- 3.2 Market Driver Analysis
  - 3.2.1 Advent Of Liquid Biopsy
  - 3.2.2 Transition Of Novel Oncology Diagnostics From Bench To Clinics
  - 3.2.3 Advancements In Quality And Payment Pertaining To Genetic Cancer Tests
- 3.3 Market Restraint Analysis
  - 3.3.1 Risks Associated With Biopsy Procedures
  - 3.3.2 Technical And Clinical Challenges
- 3.4 Market Opportunity Analysis
  - 3.4.1 Integral Role Of Biopsies In Oncology Companion Diagnostics
  - 3.4.2 Increase In The Demand For Biopsies In Translational Research
- 3.5 Market Threat Analysis
  - 3.5.1 Risk Associated With Repeat Biopsy Procedures

## **CHAPTER 4 BUSINESS ENVIRONMENT ANALYSIS**

- 4.1 SWOT Analysis; By Factor (Political & Legal, Economic, and Technological)
- 4.2 Porter's Five Forces Analysis

## **CHAPTER 5 SUPPLY CHAIN ANALYSIS**

- 5.1 Sample Collection (List of Biobanks/Center)
- 5.2 Sample Processing (List of Vendors)

## **CHAPTER 6 COST/PRICING ANALYSIS**

- 6.1 Biopsy Cost
  - 6.1.1 By Indication
    - 6.1.1.1 Typical Biopsy Costs For Patients Not Covered By Health Insurance In The U.S.
  - 6.1.2 By Type/Method
- 6.2 Key Factors Influencing The Cost
- 6.3 Costs Of Cancer Management
  - 6.3.1 Pharma Versus Diagnostics Price Analysis For Cancer Care
  - 6.3.2 U.S. Expenditures For Cancer By Source Of Payment
    - 6.3.2.1 Expenditures For Cancer Care By Year & Cancer Site, USD Million, 2010 - 2018

## **CHAPTER 7 REIMBURSEMENT AND REGULATORY ANALYSIS**

7.1 Regulatory Framework: U.S. Cancer Biopsy Market

7.2 Reimbursement Framework: U.S. Cancer Biopsy Market

## **CHAPTER 8 CHALLENGES/RESTRAINTS/COMPLICATIONS ANALYSIS**

8.1 Challenges/Restrictions/Complications Analysis

8.1.1 By Site (Organ)

8.1.2 By Method

## **CHAPTER 9 CANCER BIOPSY PRODUCT MANUFACTURERS**

## **CHAPTER 10 TYPE BUSINESS ANALYSIS**

10.1 U.S. Cancer Biopsy Market: Type Movement Analysis

10.2 U.S. Cancer Biopsy Market: Comparative Analysis of Biopsy Type

10.3 Fine Needle Aspiration

10.4 Core Needle Biopsy (CNB)

10.4.1 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)

10.4.1.1 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)

10.4.1.2 U.S. Cancer Core Needle Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)

10.5 Cancer Surgical Biopsy

10.5.1 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)

10.5.1.1 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)

10.5.1.2 U.S. Cancer Surgical Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)

10.6 Skin Biopsy/Punch Biopsy

10.6.1 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)

10.6.1.1 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)

10.6.1.2 U.S. Cancer Fine Needle Aspiration (Fna) Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)

10.6.1.3 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts, 2018 - 2030 (USD Million)

10.6.1.4 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts For Pharma Use, 2018 - 2030 (USD Million)

10.6.1.5 U.S. Skin Biopsy/Punch Cancer Biopsy Market Estimates And Forecasts For Clinical-Use, 2018 - 2030 (USD Million)

10.7 Others

10.7.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Other Types, 2018 - 2030 (USD Million)

10.7.1.1 U.S. other types cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)

10.7.1.2 U.S. other types cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)

## **CHAPTER 11 SITE (ORGAN) BUSINESS ANALYSIS**

11.1 Cancer Biopsy Market: Site (Organ) Movement Analysis

11.2 Breast

11.2.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Breast, 2018 - 2030 (USD Million)

11.3 Thyroid

11.3.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Thyroid, 2018 - 2030 (USD Million)

11.4 Uterus & Cervix

11.4.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Uterus & Cervix, 2018 - 2030 (USD Million)

11.5 Lung

11.5.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Lung, 2018 - 2030 (USD Million)

11.6 Prostate

11.6.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Prostate, 2018 - 2030 (USD Million)

11.7 Bladder

11.7.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Bladder, 2018 - 2030 (USD Million)

11.8 Kidney

11.8.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Kidney, 2018 - 2030 (USD Million)

11.9 Liver

11.9.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Liver, 2018 - 2030 (USD Million)

11.10 Pancreas

11.10.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Pancreas, 2018 - 2030 (USD Million)

11.11 Other Sites

11.11.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Other Sites, 2018 - 2030 (USD Million)

## **CHAPTER 12 APPLICATION (CAUSE) BUSINESS ANALYSIS**

12.1 U.S. Cancer Biopsy Market: Application (Cause) Movement Analysis

12.2 Screening & Monitoring

12.2.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Screening & Monitoring, 2018 - 2030 (USD Million)

12.3 Diagnostics

12.3.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Diagnostics, 2018 - 2030 (USD Million)

12.4 Investigational & Translational Research

12.4.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Investigational & Translational Research, 2018 - 2030 (USD Million)

12.5 Pharma & Biopharma Discovery & Development

12.5.1 U.S. Cancer Biopsy Market Estimates And Forecasts For Pharma & Biopharma Discovery & Development, 2018 - 2030 (USD Million)

## **CHAPTER 13 REGIONAL BUSINESS ANALYSIS**

13.1 U.S. Cancer Biopsy Market: Regional Movement Analysis

13.2 U.S.

13.2.1 U.S. Cancer Biopsy Market, 2018 - 2030 (USD Million)

## **CHAPTER 14 COMPETITIVE LANDSCAPE**

14.1 Market Participation Categorization

14.2 Strategy Framework

14.3 Vendor Landscape

14.3.1 List Of Key Distributors And Channel Partners

14.3.2 Key Customers

14.3.2.1 List Of Key Customers



- 14.3.3 Public Companies
  - 14.3.3.1 List Of Public Companies
- 14.3.4 Private Companies
  - 14.3.4.1 List Of Key Private Companies
- 14.3.5 Emerging Players
  - 14.3.5.1 List Of Key Emerging Companies
- 14.4 Major Deals And Strategic Alliances Analysis
  - 14.4.1 Mergers And Acquisitions
  - 14.4.2 Collaborations And Partnerships
  - 14.4.3 New Product Launch
- 14.5 Market Impact Analysis By Key Participants
  - 14.5.1 Ansoff Matrix
  - 14.5.2 Company/Competition Categorization (Primary & Secondary Market Participants)

## **CHAPTER 15 COMPANY PROFILES**

- 15.1 Company Profiles
  - 15.1.1 Bd (Becton, Dickinson And Company)
    - 15.1.1.1 Company Overview
    - 15.1.1.2 Financial Performance
    - 15.1.1.3 Product Benchmarking
    - 15.1.1.4 Strategic Initiatives
  - 15.1.2 Izi Medical Products
    - 15.1.2.1 Company Overview
    - 15.1.2.2 Product Benchmarking
    - 15.1.2.3 Strategic Initiatives
  - 15.1.3 Johnson & Johnson Services, Inc.
    - 15.1.3.1 Company Overview
    - 15.1.3.2 Depuy Synthes
      - 15.1.3.2.1 Company Overview
    - 15.1.3.3 Ethicon, Inc.
      - 15.1.3.3.1 Company Overview
    - 15.1.3.4 Financial Performance
    - 15.1.3.5 Product Benchmarking
  - 15.1.4 Argon Medical
    - 15.1.4.1 Company Overview
    - 15.1.4.2 Product Benchmarking
    - 15.1.4.3 Cook



- 15.1.4.4 Company Overview
- 15.1.4.5 Product Benchmarking
- 15.1.5 Spectra Medical Devices, Inc.
  - 15.1.5.1 Company Overview
  - 15.1.5.2 Product Benchmarking
- 15.1.6 Medtronic
  - 15.1.6.1 Company Overview
  - 15.1.6.2 Financial Performance
  - 15.1.6.3 Product Benchmarking
  - 15.1.6.4 Strategic Initiatives
- 15.1.7 Boston Scientific Corporation
  - 15.1.7.1 Company Overview
  - 15.1.7.2 Financial Performance
  - 15.1.7.3 Product Benchmarking
  - 15.1.7.4 Strategic Initiatives
- 15.1.8 Conmed Corporation
  - 15.1.8.1 Company Overview
  - 15.1.8.2 Financial Performance
  - 15.1.8.3 Product Benchmarking
- 15.1.9 Inrad, Inc.
  - 15.1.9.1 Company Overview
  - 15.1.9.2 Product Benchmarking
- 15.1.10 Thermo Fisher Scientific, Inc.
  - 15.1.10.1 Company Overview
  - 15.1.10.2 Financial Performance
  - 15.1.10.3 Product Benchmarking
  - 15.1.10.4 Strategic Initiatives

## List Of Tables

### LIST OF TABLES

Table 1 List of secondary sources

Table 2 Reasons for the popularity of oncology tourism in some countries

Table 3 Common types of oncology tourism treatments

Table 4 Liquid biopsy developing or commercializing companies

Table 5 Average pricing analysis: Biopsy to indication

Table 6 Average pricing analysis: Biopsy to indication

Table 7 Expenditures for cancer care by year & cancer site, USD Million, 2010 - 2018

Table 8 List of cleared/approved companion diagnostic devices (In vitro and imaging tools)

Table 9 Types of insurance coverage

Table 10 Policy structure types issued by private payers and Medicare

Table 11 Coverage policies for ctDNA

Table 12 CPT codes for minimally invasive prostate procedures

Table 13 CPT codes for office visits-new & established patient

Table 14 Surgical biopsy: Feasibility analysis across cancer diagnosis

Table 15 Comparative analysis of traditional and liquid liver biopsies

## List Of Figures

### LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Data triangulation techniques
- Fig. 3 Primary research pattern
- Fig. 4 End-use landscape: Cancer biopsy product penetration
- Fig. 5 Cancer biopsy: Market origin/parent market assessment
- Fig. 6 Market competition analysis: Early diagnosis industry sector
- Fig. 7 Market formulation & validation
- Fig. 8 U.S. cancer biopsy market outlook (2022)
- Fig. 9 U.S. cancer biopsy market driver impact
- Fig. 10 External factors driving the demand for cancer biopsy
- Fig. 11 U.S. cancer biopsy market restraint impact
- Fig. 12 SWOT analysis
- Fig. 13 Porter's five forces analysis
- Fig. 14 Key driving factors of biopsy costs
- Fig. 15 U.S. expenditures for cancer by payment source, 2018
- Fig. 16 National cancer costs projected to increase drastically by 2030, in USD Billion
- Fig. 17 U.S. out-of-pocket expenses 2014 vs. 2018
- Fig. 18 U.S. cancer management expenditure
- Fig. 19 U.S. cancer biopsy market: Type outlook and key takeaways
- Fig. 20 U.S. cancer biopsy market: Type movement analysis
- Fig. 21 Tissue biopsy vs liquid biopsy: Comparative analysis
- Fig. 22 U.S. cancer core needle biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 23 U.S. cancer core needle biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
- Fig. 24 U.S. cancer core needle biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
- Fig. 25 U.S. cancer surgical biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
- Fig. 26 U.S. cancer surgical biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)
- Fig. 27 U.S. cancer surgical biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)
- Fig. 28 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 29 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)

Fig. 30 U.S. cancer fine needle aspiration (FNA) biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)

Fig. 31 U.S. skin biopsy/punch cancer biopsy market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 32 U. S .skin biopsy /punch cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)

Fig. 33 U.S. skin biopsy /punch cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)

Fig. 34 U.S. cancer liquid biopsy market estimates and forecasts for other types, 2018 - 2030 (USD Million)

Fig. 35 U.S. other types of cancer biopsy market estimates and forecasts for pharma use, 2018 - 2030 (USD Million)

Fig. 36 U.S. other types of cancer biopsy market estimates and forecasts for clinical-use, 2018 - 2030 (USD Million)

Fig. 37 Cancer biopsy market: Site (Organ) outlook and key takeaways

Fig. 38 Cancer biopsy market: Site (Organ) movement analysis

Fig. 39 U.S. cancer biopsy market estimates and forecasts for breast, 2018 - 2030 (USD Million)

Fig. 40 U.S. cancer biopsy market estimates and forecasts for thyroid, 2018 - 2030 (USD Million)

Fig. 41 U.S. cancer biopsy market estimates and forecasts for uterus & cervix, 2018 - 2030 (USD Million)

Fig. 42 U.S. cancer biopsy market estimates and forecasts for lung, 2018 - 2030 (USD Million)

Fig. 43 U.S. cancer biopsy market estimates and forecasts for prostate, 2018 - 2030 (USD Million)

Fig. 44 U.S. cancer biopsy market estimates and forecasts for bladder, 2018 - 2030 (USD Million)

Fig. 45 U.S. cancer biopsy market estimates and forecasts for kidney, 2018 - 2030 (USD Million)

Fig. 46 U.S. cancer biopsy market estimates and forecasts for liver, 2018 - 2030 (USD Million)

Fig. 47 U.S. cancer biopsy market estimates and forecasts for pancreas, 2018 - 2030 (USD Million)

Fig. 48 U.S. cancer biopsy market estimates and forecasts for other sites, 2018 - 2030 (USD Million)

Fig. 49 U.S. cancer biopsy market: Application (Cause) outlook and key takeaways

- Fig. 50 U.S. cancer biopsy market: Application (Cause) movement analysis
- Fig. 51 U.S. cancer biopsy market estimates and forecasts for screening & monitoring, 2018 - 2030 (USD Million)
- Fig. 52 U.S. cancer biopsy market estimates and forecasts for diagnostics, 2018 - 2030 (USD Million)
- Fig. 53 U.S. cancer biopsy market estimates and forecasts for investigational & translational research, 2018 - 2030 (USD Million)
- Fig. 54 U.S. cancer biopsy market estimates and forecasts for pharma & biopharma discovery & development, 2018 - 2030 (USD Million)
- Fig. 55 U.S. cancer biopsy market, 2018 - 2030 (USD million)
- Fig. 56 Participant categorization - U.S. cancer biopsy market
- Fig. 57 Strategy framework - U.S. cancer biopsy market
- Fig. 58 Ansoff matrix
- Fig. 59 Competition categorization

## I would like to order

Product name: U.S. Cancer Biopsy Market Size, Share & Trends Analysis Report By Type (Fine-needle Aspiration, Core, Surgical, Skin Biopsy/Punch Biopsy), By Application, By Site, And Segment Forecasts, 2023 - 2030

Product link: <https://marketpublishers.com/r/UFAB77340994EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UFAB77340994EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970